Loading clinical trials...
Loading clinical trials...
A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
Conditions
Interventions
Oleclumab
Durvalumab
+5 more
Locations
27
United States
Research Site
La Jolla, California, United States
Research Site
Aurora, Colorado, United States
Research Site
Fort Myers, Florida, United States
Research Site
Atlanta, Georgia, United States
Research Site
Boston, Massachusetts, United States
Research Site
Boston, Massachusetts, United States
Start Date
June 21, 2018
Primary Completion Date
July 22, 2022
Completion Date
July 22, 2022
Last Updated
October 3, 2023
NCT04929028
NCT04550494
NCT03191149
NCT03647358
NCT03375307
NCT05673200
Lead Sponsor
MedImmune LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions